Why the study?
It was unknown whether myocardial fibrosis and greyzone fibrosis on CMR are associated with ventricular arrhythmias in patients with CAD and LVEF >35%.
Is greyzone myocardial fibrosis on CMR associated with ventricular arrhythmias in patients with CAD and LVEF >35%?
Is greyzone myocardial fibrosis on CMR associated with ventricular arrhythmias in patients with CAD and LVEF >35%?
Greyzone fibrosis mass assessed by CMR is a strong predictor of ventricular arrhythmias in patients with CAD and LVEF >35%.
Answers are grounded in this paper and cite their sources.
Greyzone fibrosis on CMR may refine arrhythmia risk stratification in CAD with LVEF >35%; hypothesis-generating pending prospective validation.
AIMS: To determine whether myocardial fibrosis and greyzone fibrosis (GZF) on cardiovascular magnetic resonance (CMR) is associated with ventricular arrhythmias in patients with coronary artery disease (CAD) and a left ventricular ejection fraction (LVEF) >35%. METHODS AND RESULTS: In this retrospective study of CAD patients, GZF mass using the 3SD method (GZF3SD) and total fibrosis mass using the 2SD method (TF2SD) on CMR were assessed in relation to the primary, combined endpoint of sudden cardiac death, ventricular tachycardia, ventricular fibrillation, or resuscitated cardiac arrest. Among 701 patients [age: 65.8 ± 12.3 years (mean ± SD)], 28 (3.99%) patients met the primary endpoint over 5.91 years (median; interquartile range 4.42-7.64). In competing risks analysis, a GZF3SD mass ≥5.0 g was strongly associated with the primary endpoint [subdistribution hazard ratio (sHR): 17.4 (95% confidence interval, CI 6.64-45.5); area under receiver operator characteristic curve (AUC): 0.85, P < 0.001]. A weaker association was observed for TF2SD mass ≥23 g [sHR 10.4 (95% CI 4.22-25.8); AUC: 0.80, P < 0.001]. The range of sHRs for GZF3SD mass (1-527) was wider than for TF2SD mass (1-37.6). CONCLUSIONS: In CAD patients with an LVEF >35%, GZF3SD mass was strongly associated with the arrhythmic endpoint. These findings hold promise for its use in identifying patients with CAD and an LVEF >35% at risk of arrhythmic events.
No takes yet. Share an insight, caveat, or question.
Zegard et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: